Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke

• DOI: 10.1371/journal.pone.0134193
• Publication Date: 2015-08-25T18:19:17Z
• Authors: Hyacinth I. Hyacinth; Robert J. Adams; Charles S. Greenberg; Jenifer H. Voeks; Allyson Hill; Jacqueline M. Hib...; Beatrice E. Gee
• Keywords: Transcranial Doppler; Stroke; D-dimer; Transfusion Therapy

Hypercoagulability in sickle cell disease (SCD) is associated with multiple SCD phenotypes, association stroke risk has not been well described. We hypothesized that serum levels of biomarkers coagulation activation correlate high transcranial Doppler ultrasound velocity and decreases blood transfusion therapy patients. Stored samples from subjects the Stroke Prevention Sickle Cell Anemia (STOP) trial were analyzed using ELISA protein multiplexing techniques. 40 each treatment arm (Standard Care [SC] Transfusion [Tx]) at three time points—baseline, study exit one year post-trial 10 age matched children but normal TCD (SNTCD) hemoglobin (HbAA) analyzed. At baseline, median vWF, TAT D-dimer significantly higher among STOP than either HbAA or SNTCD. exit, level was while lower Tx compared to SC subjects. Median vWF (409.6 vs. 542.9 μg/ml), (24.8 40.0 ng/ml) (9.2 19.1 μg/ml) also group exit. Blood activation/thrombin generation correlated positively negatively number transfusions. Biomarkers elevated SCD, for stroke. Reduction these reduction (lower velocity), indicating a possible role hypercoagulation